

Pluvia Biotech Announces Research Collaboration with PTC Therapeutics

Bergen, Norway, 15 April 2024 – Pluvia Biotech (Pluvia), a company dedicated to developing pharmacological chaperones for the treatment of Phenylketonuria (PKU), announces that it has established a research collaboration with PTC Therapeutics (PTC), a global biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for patients with rare disorders.

Over the years Pluvia has developed deep scientific knowledge regarding PKU and comprehensive models and methods to support the development of therapeutics.

“We are very proud to be preparing global regulatory submissions for sepiapterin, our promising and differentiated therapy being developed for children and adults with PKU,” said Matthew B. Klein, M.D., PTC Chief Executive Officer. “A collaboration with the expert team at Pluvia allows us to continue to pursue our interest in building on our inborn errors of metabolism platform.”

Willem van Weperen, CEO of Pluvia adds: “This research collaboration recognizes the scientific progress of our company and validates our ability to contribute to innovation and drug development.”

About PKU

Phenylketonuria (PKU), also known as Føllings disease (named after the Norwegian physician Ivar Asbjørn Følling, the first to identify the disease in 1934), is a rare genetic disorder characterized by the body's inability to break down the amino acid phenylalanine due to a deficiency in the enzyme phenylalanine hydroxylase (PAH), caused by genetic variants. This results in the accumulation of phenylalanine in the bloodstream, leading to intellectual disabilities and other neurological problems if left untreated. Patients need a strict lifelong diet without regular protein intake to prevent cognitive impairment.

About Pluvia Biotech

Pluvia Biotech is a spin-out from the University of Bergen (Norway) dedicated to addressing orphan diseases from protein misfolding with a high unmet medical need. The company's lead program is focused on developing a "first in class" oral pharmacological chaperone treatment of Phenylketonuria (PKU). Through pioneering research and development, Pluvia aims to provide PKU patients with the opportunity to live life without the dietary constraints imposed by the condition. Pluvia's progress is supported by investors Sarsia, Trond Mohn Foundation and Investinor.

For more information about Pluvia Biotech and its innovative work in PKU treatment development, please visit www.pluviabiotech.com. For media inquiries and additional information, please contact info@pluviabiotech.com